Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
IPhEB Russia
Not Confirmed
Contact SupplierIPhEB Russia
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content
NEWS #PharmaBuzz
20 Apr 2022
// BUSINESSWIRE
19 Jul 2021
// BUSINESSWIRE
10 Jun 2021
// CLINICAL TRAILS ARENA
https://www.clinicaltrialsarena.com/news/selva-drug-activity-variants/
09 Jun 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210609005298/en/Selva-Announces-SLV213-a-Potential-Oral-COVID-19-Treatment-Has-Broad-Activity-Against-SARS-CoV-2-Variants-of-Concern
02 Feb 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210202005408/en/Selva-Therapeutics-Announces-Successful-Completion-of-Phase-1-Clinical-Study-of-SLV213-a-Potential-Oral-Treatment-for-COVID-19
12 Nov 2020
// BUSINESSWIRE
Drugs in Development
Details:
New preclinical data demonstrated, that dosing of SLV213 at picomolar concentrations delivered near-complete inhibition of infection by the Omicron variant of SARS-CoV-2 in a human lung epithelial cell line (A549_ACE2).
Lead Product(s): SLV213
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 20, 2022
Lead Product(s) : SLV213
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New preclinical data demonstrated, that dosing of SLV213 at picomolar concentrations delivered near-complete inhibition of infection by the Omicron variant of SARS-CoV-2 in a human lung epithelial cell line (A549_ACE2).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2022
Details:
SLV213 is a novel, orally available, small molecule antiviral investigational drug that inhibits human host cell cysteine proteases to block viral entry.
Lead Product(s): SLV213
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 19, 2021
Lead Product(s) : SLV213
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SLV213 is a novel, orally available, small molecule antiviral investigational drug that inhibits human host cell cysteine proteases to block viral entry.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2021
Details:
Company has received U.S. FDA clearance of an Investigational New Drug Application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Preclinical data show SLV213 is a potent inhibitor of SARS-CoV-2 infection.
Lead Product(s): SLV213
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2020
Lead Product(s) : SLV213
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company has received U.S. FDA clearance of an Investigational New Drug Application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Preclinical data show SLV213 is a potent inhibitor of SARS-CoV-2 inf...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2020
Details:
The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.
Lead Product(s): SLV213
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 21, 2020
Lead Product(s) : SLV213
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $3.0 million
Deal Type : Series A Financing
Details : The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
